New Trial: Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
This is one of my favorite neurosurgeons.. when I first heard about him using Avastin in the way, I thought it was crazy, but after having him explain the thinking behind it, it makes a lot of sense. I videotaped his explanation - go to www.virtualtrials.com/video2012.cfm for the video.
This might be a better way to use Avastin.
Posted on: 03/20/2013
Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab for Treatment of Newly Diagnosed Glioblastoma Multiforme
PI: John Boockvar, MD
Dr. John Boockvar and the Weill Cornell Brain Tumor Center are pleased to announce the opening of a new clinical trial for glioblastoma multiforme (GBM). The trial is a Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for patients with newly diagnosed GBM. We have shown in a previous phase I trial that Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab is safe and effective (more than doubles the progression free survival) in the treatment of recurrent GBM. Therefore, this phase I/II clinical research trial is an extension of that trial in that we seek to test the hypothesis that repeated dosing of intra-arterial Bevacizumab is safe and effective in the treatment of newly diagnosed malignant glioma. By achieving the aims of this study we will also determine if repeated intra-arterial Bevacizumab improves progression free and overall survival in newly diagnosed patients. We expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for malignant glioma, and may alter the way these drugs are delivered to our patients in the near future.
If you would like more information regarding the trial please contact Tamika Wong, MPH, Clinical Research Coordinator at 212-746-1788 or email@example.com or Dr. John Boockvar at 212-746-1996 or firstname.lastname@example.org.
Click HERE to return to brain tumor news headlines